Stem cell-based disease models for inborn errors of immunity

Zbinden, A.; Cante-Barrett, K.; Pike-Overzet, K.; Staal, F.J.T. (2022)

Article / Letter to editor

The intrinsic capacity of human hematopoietic stem cells (hHSCs) to reconstitute myeloid and lymphoid lineages combined with their self-renewal capacity hold enormous promises for gene therapy as a viable treatment option for a number of immune-mediated diseases, most prominently for inborn errors of immunity (IEI). The current development of such therapies relies on disease models, both in vitro and in vivo, which allow the study of human pathophysiology in great detail. Here, we discuss the current challenges with regards to developmental origin, heterogeneity and the subsequent implications for disease modeling. We review models based on induced pluripotent stem cell technology and those relaying on use of adult hHSCs. We critically review the advantages and limitations of current models for IEI both in vitro and in vivo. We conclude that existing and future stem cell-based models are necessary tools for developing next generation therapies for IEI.

• hematopoietic stem cells
• induced pluripotent stem cells
• immune deficiency
• inborn errors of immunity
• primary immune deficiency

• All authors: Zbinden, A.; Cante-Barrett, K.; Pike-Overzet, K.; Staal, F.J.T.
• Date: 2022-01-01
• Journal: Cells
• Volume: 11
• Issue: 1
• DOI: doi:10.3390/cells11010108
• Link: https://www.mdpi.com/2073-4409/11/1/108